Print Page | Sign In | Join Today
News & Press: Company News

Serpin Pharma Begins Phase I Clinical Trial & Awarded $350K from Virginia Catalyst

Wednesday, August 8, 2018  
Share |
Serpin Pharma launched its Phase I clinical study on July 24. The first subject was treated with Serpin Pharma’s drug, SP16, at Virginia Commonwealth University (VCU) Medical Center. The company expects to complete the study before the end of the year, and initiate Phase II studies for the treatment of Acute Myocardial Infarct in 2Q 2019.

Additionally, Serpin Pharma’s $350K proposal to the Virginia BioCatalyst Fund was chosen by the fund's board of directors. The focus of the winning proposal is twofold. One arm will focus on an extensive Proof of Concept studies for the use of SP16 in Traumatic Brain Injury. This research program is conducted in collaboration with a renowned team of neuroscientists at VCU. The second arm will focus on the development of an orally available, small molecule drug modeled on SP16 drug. This research program is conducted by a group of three leading scientists from George Mason University – Profs. Lance Liotta, Alessandra Luchini, and Mikell Paige.

Serpin Pharma operates within Prince William County Science Accelerator and is led by serial entrepreneurs in the biotech field – Dr. Cohava Gelber and Guy Yachin.

Our Premium Partners

Sign up for our newsletter
800 E. Leigh St.  |  Richmond, Va 23219-1534  |  PH: 804.643.6360  |  Email Us
Stay Connected